FDA approves new adaptation of INVOKANA

recently, Johnson and Johnson's JanssenPharmaceutical(Inc.)(The U.SFDA(approved INVOKANA, canagliflozin) new adaptation to reduce the risk of cardiovascular heart disease, stroke or death in adults with type 2 diabetes (T2D) for major cardiovascular events (CV)studyCANVAS (CANagliflozin Cardiovascular Assessment Study)experimental(assessing the impact of INVOKANA on CV risk in more than 10,000 adult T2D patients, 65 percent of whom had CV disease and 35 percent had two or more risk factors for CV)overall,, INVOKANA reduced the risk of combined heart attack, stroke and CV death by 14% compared to placebo (26.9 and 31.5 per 1,000 patients; HR: 0.86; 95% CI: 0.75-0.97; non-effect P 0.0001, and good-effect P.0.0158)Among patients, the combined risk of INVOKANA treatment for heart disease, stroke and CV death was reduced by 18% compared to placebo (34.1 and 41.3 per 1,000 people, respectively; HR: 0.82; 95% CI: 0.72-0.95),on inINKANAVO INVOKANA prescription drugs developed by Mitsubishi Tanabe and sold by Johnson and Johnson.com.comPreviously approved to lower blood sugar in people with type 2 diabetes along with diet and exercise, but not for type 1 diabetes or ketoacidosis (increased ketones in blood or urine)it is not clear whether INVOKANA is safe and effective for children under the age of 18INVOKANA's active ingredient, canagliflozin, is an inhibitor of subtype 2 sodium-glucose transfer protein (SGLT2), which is responsible for at least 90% of renal glucose reabsorption (SGLT1 is responsible for the remaining 10%), blocking this transport protein can cause up to 119 grams of blood sugar per day through urine However, this mechanism is associated with the risk of hypoglycemia (hypoglycemia) compared to sulfonylurea derivatives and insulin 2017, the FDA concluded that cagully can lead to an increased risk of leg and foot amputations and asked to add boxed warnings to drug (labels) to describe the risk